结肠镜检查的影像学替代方法:CT结肠成像与结肠胶囊内镜——欧洲消化内镜学会(ESGE)与欧洲胃肠道和腹部放射学会(ESGAR)指南2020年更新
该指南2020年更新由ESGE与ESGAR制定,采用GRADE系统分级,针对无法或不宜行结肠镜检查的患者,系统评价CT结肠成像(CTC)与结肠胶囊内镜(CCE)的临床适应证并给出推荐。推荐CTC作为结直肠肿瘤诊断的首选放射学检查(强推荐,高质量证据),不推荐钡剂灌肠;CCE在部分场景为弱推荐。
要点
- CTC被强推荐为结直肠肿瘤诊断的首选放射学检查,不推荐钡剂灌肠(强推荐,高质量证据)。
- 结肠镜检查不完全时推荐CTC(最好同日或次日,强推荐,低质量证据);有CCE专长与条件的中心可考虑CCE(弱推荐)。
- CTC或CCE检出至少一个≥6 mm息肉时应转诊内镜息肉切除术(强推荐,中等质量证据)。
核心结论
- CTC是诊断结直肠肿瘤的首选放射学检查(强推荐,高质量证据),不推荐钡剂灌肠(强推荐,高质量证据)。
- 结肠镜检查不完全时推荐CTC(强推荐,低质量证据);有CCE专长与条件的中心可考虑CCE(弱推荐,低质量证据)。
- 结肠镜检查禁忌或不可行时,对有报警症状者推荐CTC(强推荐,高质量证据),不推荐CCE(极低质量证据);对无报警症状者推荐CTC(强推荐,高质量证据),有条件的中心可考虑CCE(弱推荐,低质量证据)。
- 无组织性FIT筛查项目时推荐CTC作为筛查选项(强推荐,高质量证据),不建议CCE作为一线筛查(弱推荐,低质量证据)。
- FOBT或FIT阳性且结肠镜不完全或不可行时推荐CTC(强推荐,中等质量证据),有条件时建议CCE(弱推荐,中等质量证据)。
研究设计与样本
- 本指南为ESGE与ESGAR 2014-15版指南的更新,针对影像学替代标准结肠镜的临床适应证。
- 采用针对性文献检索评价CTC与CCE的证据,并采用GRADE系统确定推荐强度与证据质量。
诊断标准与关键数值
- CTC或CCE检出至少一个≥6 mm息肉应转诊内镜息肉切除术(强推荐,中等质量证据)。
- CTC检出6-9 mm病变若患者因选择、合并症和/或晚期肿瘤低风险未行息肉切除,可临床考虑随访CTC(强推荐,中等质量证据)。
- 对结直肠癌根治性切除术后监测,仅结肠镜禁忌或不可行时建议静脉对比剂增强CTC(弱推荐,低质量证据);证据不足以推荐CCE(极低质量证据)。
- 息肉切除术后监测中,仅结肠镜不可行时建议CTC(弱推荐,低质量证据);证据不足以推荐CCE(极低质量证据)。
临床应用与阅片要点
- CTC被强推荐为结直肠肿瘤诊断的首选放射学检查,不推荐钡剂灌肠(强推荐,高质量证据)。
- 结肠镜检查不完全时推荐CTC,最好同日或次日,时机取决于内镜与放射因素的多学科决策(强推荐,低质量证据);有CCE专长与条件的中心可考虑CCE,最好同日或次日(弱推荐,低质量证据)。
- 急性结肠炎症及近期结直肠手术患者不推荐CTC,需多学科评估(强推荐,低质量证据)。
局限性
- 关于CCE在有报警症状患者中应用,因缺乏直接证据而不推荐(极低质量证据)。
- CCE用于结直肠癌根治性切除术后监测证据不足(极低质量证据)。
- CCE用于息肉切除术后监测证据不足(极低质量证据)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
1. ESGE/ESGAR recommend computed tomographic colonography (CTC) as the radiological examination of choice for the diagnosis of colorectal neoplasia. Strong recommendation, high quality evidence. ESGE/ESGAR do not recommend barium enema in this setting. Strong recommendation, high quality evidence.2. ESGE/ESGAR recommend CTC, preferably the same or next day, if colonoscopy is incomplete. The timing depends on an interdisciplinary decision including endoscopic and radiological factors. Strong recommendation, low quality evidence. ESGE/ESGAR suggests that, in centers with expertise in and availability of colon capsule endoscopy (CCE), CCE preferably the same or the next day may be considered if colonoscopy is incomplete. Weak recommendation, low quality evidence.3. When colonoscopy is contraindicated or not possible, ESGE/ESGAR recommend CTC as an acceptable and equally sensitive alternative for patients with alarm symptoms. Strong recommendation, high quality evidence. Because of lack of direct evidence, ESGE/ESGAR do not recommend CCE in this situation. Very low quality evidence. ESGE/ESGAR recommend CTC as an acceptable alternative to colonoscopy for patients with non-alarm symptoms. Strong recommendation, high quality evidence. In centers with availability, ESGE/ESGAR suggests that CCE may be considered in patients with non-alarm symptoms. Weak recommendation, low quality evidence.4. Where there is no organized fecal immunochemical test (FIT)-based population colorectal screening program, ESGE/ESGAR recommend CTC as an option for colorectal cancer screening, providing the screenee is adequately informed about test characteristics, benefits, and risks, and depending on local service- and patient-related factors. Strong recommendation, high quality evidence. ESGE/ESGAR do not suggest CCE as a first-line screening test for colorectal cancer. Weak recommendation, low quality evidence.5. ESGE/ESGAR recommend CTC in the case of a positive fecal occult blood test (FOBT) or FIT with incomplete or unfeasible colonoscopy, within organized population screening programs. Strong recommendation, moderate quality evidence. ESGE/ESGAR also suggest the use of CCE in this setting based on availability. Weak recommendation, moderate quality evidence.6. ESGE/ESGAR suggest CTC with intravenous contrast medium injection for surveillance after curative-intent resection of colorectal cancer only in patients in whom colonoscopy is contraindicated or unfeasible. Weak recommendation, low quality evidence. There is insufficient evidence to recommend CCE in this setting. Very low quality evidence.7. ESGE/ESGAR suggest CTC in patients with high risk polyps undergoing surveillance after polypectomy only when colonoscopy is unfeasible. Weak recommendation, low quality evidence. There is insufficient evidence to recommend CCE in post-polypectomy surveillance. Very low quality evidence.8. ESGE/ESGAR recommend against CTC in patients with acute colonic inflammation and in those who have recently undergone colorectal surgery, pending a multidisciplinary evaluation. Strong recommendation, low quality evidence.9. ESGE/ESGAR recommend referral for endoscopic polypectomy in patients with at least one polyp ≥6 mm detected at CTC or CCE. Follow-up CTC may be clinically considered for 6-9-mm CTC-detected lesions if patients do not undergo polypectomy because of patient choice, comorbidity, and/or low risk profile for advanced neoplasia. Strong recommendation, moderate quality evidence. Source and scope This is an update of the 2014-15 Guideline of the European Society of Gastrointestinal Endoscopy (ESGE) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR). It addresses the clinical indications for the use of imaging alternatives to standard colonoscopy. A targeted literature search was performed to evaluate the evidence supporting the use of computed tomographic colonography (CTC) or colon capsule endoscopy (CCE). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was adopted to define the strength of recommendations and the quality of evidence.
引用
- Spada C, Hassan C, Bellini D, et al. Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline - Update 2020. Eur Radiol. 2021. PMID: 33104846. doi:10.1007/s00330-020-07413-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。